Physician profile
Marc S Werner
NPI 1760462048
$4,141.24
in general payments reported to CMS, 2019-2025
27 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $689 · 2021: $382 · 2022: $737 · 2023: $662 · 2024: $697 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.17 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $753.98 | 2019-2023 | Tepezza |
| Merz Pharmaceuticals, LLC | $383.37 | 2021-2025 | Xeomin |
| Carl Zeiss Meditec, INC. | $358.60 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $268.84 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $262.57 | 2019-2021 | |
| Oyster Point Pharma, INC. | $214.06 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $207.28 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $184.94 | 2020-2023 | Cequa, Xelpros |
| Ani Pharmaceuticals, INC. | $174.66 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $157.13 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Amgen INC. | $157.02 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $150.43 | 2021-2023 | |
| Alcon Vision LLC | $134.20 | 2020-2025 | Simbrinza |
| Kala Pharmaceuticals, INC. | $111.23 | 2020-2022 | |
| Glaukos Corporation | $100.37 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $84.94 | 2021-2023 | |
| Allergan, INC. | $69.73 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $64.85 | 2023-2024 | Miebo, Xiidra |
| Shire North American Group INC | $58.50 | 2019 | |
| Dompe US, INC. | $51.86 | 2021-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $47.28 | 2021-2022 | |
| Sight Sciences, INC. | $46.32 | 2023 | Tearcare System |
| Rxsight INC | $29.46 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Beaver-Visitec International, INC. | $20.90 | 2023 | |
| Mallinckrodt Hospital Products INC. | $19.36 | 2022 | |
| Astellas Pharma US INC | $14.85 | 2024 | Izervay |
| Coopervision INC. | $14.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.